Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 6/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL837422 | 0.86 | — | — | |
| SCHEMBL9437006 | 0.78 | LPAR3 (0.55) | LPAR3LPAR2LPAR1SMPD1GGPS1 | |
| SCHEMBL9437036 | 0.78 | LPAR3 (0.55) | LPAR3LPAR2LPAR1SMPD1GGPS1 | |
| SCHEMBL837820 | 0.75 | — | — | |
| SCHEMBL9437032 | 0.72 | LPAR3 (0.59) | LPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL9437024 | 0.72 | LPAR3 (0.59) | LPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL187642 | 0.71 | LPAR3 (0.58) | LPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL4335107 | 0.71 | LPAR3 (0.58) | LPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL8976923 | 0.71 | LPAR3 (0.58) | LPAR3LPAR2LPAR1GGPS1 | |
| SCHEMBL8976933 | 0.71 | LPAR3 (0.58) | LPAR3LPAR2LPAR1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1793823-B1 | PHOSPHATE CONTAINING PRODRUGS OF SULFONYL HYDRAZINES AS HYPOXIA-SELECTIVE ANTINEOPLASTIC AGENTS | VION PHARMACEUTICALS INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20090075945-A1 | Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents | VION PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7405317-B2 | Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents | VION PHARMACEUTICALS INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1793823-A2 | SULFONYL HYDRAZINES AS HYPOXIA-SELECTIVE ANTINEOPLASTIC AGENTS | Vion Pharmaceuticals, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20060089332-A1 | Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents | NANOSHIFT, LLC | 2006-04-27 | — | — | US | disclosed |
| WO-2006034266-A2 | SULFONYL HYDRAZINES AS HYPOXIA-SELECTIVE ANTINEOPLASTIC AGENTS | VION PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089332-A1 | Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents | HIF1AN, HIF1A, EGLN3 | LPAR3 2599/4885LPAR2 3338/4885LPAR1 3745/4885 |
| US-20090075945-A1 | Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents | HIF1AN, HIF1A, SLC20A1 | LPAR3 1595/4885LPAR2 2485/4885LPAR1 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.